# US 9,872,914 B2 · Solid pharmaceutical composition containing 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or salt thereof > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 9,872,914 B2 - Document ID: US9872914B2 - Status: Granted - Kind: B2 - Application number: 14/379,960 - Filed: 2013-02-21 - Published: 2015-02-12 - Granted: 2018-01-23 - Earliest claimed: 2012-02-22 - Assignees: Toyama Chemical Co., Ltd. - Applicants: Toyama Chemical Co., Ltd. - Inventors: Hiroyuki Inaba; Mitsuhiro Nagata - Web page: https://patentgrep.com/patent/US9872914B2 ## CPC - A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin - A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates} - A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates} - A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose} - A61K 9/2095: {Tabletting processes} - A61K 9/282: {Organic compounds, e.g. fats} - A61K 9/2866: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose} - A61K 31/397: having four-membered rings, e.g. azetidine - A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers - A61P 25/00: Drugs for disorders of the nervous system - C07D 409/12: linked by a chain containing hetero atoms as chain links - A61K 9/2059: {Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin} - A61K 9/288: {Compounds of unknown constitution, e.g. material from plants or animals (oils, fats, waxes, shellac A61K9/282)} - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08) ## Abstract This solid pharmaceutical composition is useful as a solid pharmaceutical composition of 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol, which is excellently elutable and moldable and is stable in long-term storage, or a salt thereof. ## Claims ### Claim 1 A solid pharmaceutical tablet composition, comprising: 44% to 89% of 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof; 6% to 51% of at least one selected from the group consisting of mannitol, sorbitol, and isomaltose; 3% to 5% of a disintegrant selected from the group consisting of carmellose, carmellose calcium, croscarmellose sodium, low-substituted hydroxypropylcellulose, sodium carboxymethyl starch, partially pregelatinized starch, crospovidone, and a combination thereof; and 1% to 2% of a lubricant selected from the group consisting of magnesium stearate, sodium stearyl fumarate, and a combination thereof. ### Claim 2 (depends on 1) The solid pharmaceutical tablet composition of claim 1, which comprises mannitol. ### Claim 3 (depends on 1) The solid pharmaceutical tablet composition of claim 1, wherein the 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or the salt thereof is present in an amount of from 45% to 87% of a total weight of the solid pharmaceutical tablet composition. ### Claim 4 (depends on 1) The solid pharmaceutical tablet composition of claim 1, wherein the disintegrant is at least one selected from the group consisting of carmellose, carmellose calcium, croscarmellose sodium, and low-substituted hydroxypropylcellulose. ### Claim 5 (depends on 1) The solid pharmaceutical tablet composition of claim 1, wherein the disintegrant is at least one selected from the group consisting of carmellose, carmellose calcium, and croscarmellose sodium. ### Claim 6 (depends on 1) The solid pharmaceutical tablet composition of claim 1, wherein the lubricant is present in an amount of 1.5% of a total weight of the solid pharmaceutical tablet composition. ### Claim 7 (depends on 1) The solid pharmaceutical tablet composition of claim 1, wherein the lubricant is magnesium stearate. ### Claim 8 (depends on 1) The solid pharmaceutical tablet composition of claim 1, wherein the tablet is a film-coated tablet. ### Claim 9 (depends on 1) The solid pharmaceutical tablet composition of claim 1, which comprises sorbitol. ### Claim 10 (depends on 1) The solid pharmaceutical tablet composition of claim 1, which comprises isomaltose. ### Claim 11 (depends on 1) The solid pharmaceutical tablet composition of claim 1, wherein the solid pharmaceutical tablet composition has a hardness of from 69 to 123N. ### Claim 12 (depends on 1) The solid pharmaceutical tablet composition of claim 1, wherein the solid pharmaceutical tablet composition has a dissolution rate of 85% or more after 15 minutes, and the dissolution rate is measured by a paddle method comprising setting a number of paddle revolution at 50 rpm, adding a sample of the solid pharmaceutical tablet composition to 900 mL of a test solution having a pH value of 6.8 and comprising water, potassium dihydrogen phosphate, and sodium hydroxide, leaving the test solution to which the sample is added for 15 minutes, and determining the dissolution rate of the 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or the salt thereof by an optical density method. ### Claim 13 (depends on 1) The solid pharmaceutical tablet composition of claim 1, wherein the solid pharmaceutical tablet composition has a hardness of from 69 to 123N and a dissolution rate of 85% or more after 15 minutes, and the dissolution rate is measured by a paddle method comprising setting a number of paddle revolution at 50 rpm, adding a sample of the solid pharmaceutical tablet composition to 900 mL of a test solution having a pH value of 6.8 and comprising water, potassium dihydrogen phosphate, and sodium hydroxide, leaving the test solution to which the sample is added for 15 minutes, and determining the dissolution rate of the 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or the salt thereof by an optical density method. ### Claim 14 (depends on 1) The solid pharmaceutical tablet composition of claim 1, wherein the disintegrant comprises croscarmellose sodium. ### Claim 15 (depends on 2) The solid pharmaceutical tablet composition of claim 2, wherein the disintegrant is croscarmellose sodium, and the lubricant is magnesium stearate. ### Claim 16 (depends on 2) The solid pharmaceutical tablet composition of claim 2, wherein the 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or the salt thereof is present in an amount of from 44% to 75% of a total weight of the solid pharmaceutical tablet composition, the mannitol is present in an amount of from 6% to 49% of the total weight of the solid pharmaceutical tablet composition, the disintegrant is croscarmellose sodium, and the lubricant is magnesium stearate.